Sandra Calvin, the chief accounting officer and principal accounting officer, announced her intention to retire in February 2027 following the filing of the company's Annual Report on Form 10-K. John Torell, the current Vice President and Controller, is expected to succeed her in those roles to ensure an orderly transition. Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

William Rote, Ph.D., Chief Research Officer, announced his intention to retire on February 17, 2027. Jula Inrig, M.D., current Chief Medical Officer, will be named Executive Vice President, Head of Research & Development and Chief Medical Officer effective July 1, 2026. Travere Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutic solutions for rare diseases.